DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including Esophageal Squamous Cell Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Esophageal Squamous Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Esophageal Squamous Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Esophageal Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report
- DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
- The leading Esophageal Squamous Cell Carcinoma Companies includes BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, and others.
- Promising Esophageal Squamous Cell Carcinoma Pipeline Therapies includes KN046, Tislelizumab, IBI308, paclitaxel/ irinotecan, Anlotinib, LJM716, BYL719, Cisplatin, Oxaliplatin, and others.
- The Esophageal Squamous Cell Carcinoma companies and academics that are working to assess challenges and seek opportunities that could influence Esophageal Squamous Cell Carcinoma R&D. The Esophageal Squamous Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.
To explore more information on the latest breakthroughs in the Esophageal Squamous Cell Carcinoma Pipeline treatment landscape of the report, click here @ Esophageal Squamous Cell Carcinoma Pipeline Outlook
Esophageal Squamous Cell Carcinoma Overview
Esophageal Squamous Cell Carcinoma is the most common form of esophageal cancer worldwide. Although it is no longer the most common form of esophageal carcinoma in Western societies, ESCC continues to be the most prevalent type of esophageal cancer in the East, representing 90% of all cancers in most Asian, African, and Eastern European countries. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics. The average age of onset of ESCC is between the ages of 60 to 70 years and it is more frequently seen in males. It is usually asymptomatic until an advanced disease stage with common presenting symptoms being dysphagia (at first with solids then progressing to fluids) and weight loss. Less commonly odynophagia, hoarseness of voice, coughing, or chest pain can be presenting features. Tumors are typically found in the middle and the upper third of the esophagus. The exact etiology is unknown.
Esophageal Squamous Cell Carcinoma Emerging Drugs Profile
Tislelizumab: BeiGene
Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.
Serplulimab: Shanghai Henlius Biotech
Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).
Request a sample and discover the recent advances in Esophageal Squamous Cell Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Esophageal Squamous Cell Carcinoma Treatment Landscape
Esophageal Squamous Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Esophageal Squamous Cell Carcinoma. The companies which have their Esophageal Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, BeiGene.
Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report
- Coverage- Global
- Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, and others.
- Esophageal Squamous Cell Carcinoma Pipeline Therapies- KN046, Tislelizumab, IBI308, paclitaxel/ irinotecan, Anlotinib, LJM716, BYL719, Cisplatin, Oxaliplatin, and others
- Esophageal Squamous Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of administration
Dive deep into rich insights for drugs for Esophageal Squamous Cell Carcinoma Market Drivers and Esophageal Squamous Cell Carcinoma Market Barriers, click here @ Esophageal Squamous Cell Carcinoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Esophageal Squamous Cell Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Esophageal Squamous Cell Carcinoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tislelizumab: BeiGene
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RAPA-201: Rapa Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SGN-B6A: Seagen
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Esophageal Squamous Cell Carcinoma Key Companies
- Esophageal Squamous Cell Carcinoma Key Products
- Esophageal Squamous Cell Carcinoma- Unmet Needs
- Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
- Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
- Esophageal Squamous Cell Carcinoma Analyst Views
- Esophageal Squamous Cell Carcinoma Key Companies
- Appendix
Got Queries? Find out the related information on Esophageal Squamous Cell Carcinoma Mergers and acquisitions, Esophageal Squamous Cell Carcinoma Licensing activities @ Esophageal Squamous Cell Carcinoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services